Endo International PLC (ENDP) Scheduled to Post Quarterly Earnings on Thursday
Endo International PLC (NASDAQ:ENDP) (TSE:ENL) will be releasing its earnings data before the market opens on Thursday, November 9th. Analysts expect Endo International PLC to post earnings of $0.66 per share for the quarter. Endo International PLC has set its FY17 guidance at $3.35-3.65 EPS.
Endo International PLC (NASDAQ:ENDP) (TSE:ENL) last announced its quarterly earnings results on Tuesday, August 8th. The company reported $0.93 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.74 by $0.19. Endo International PLC had a positive return on equity of 37.58% and a negative net margin of 126.93%. The firm had revenue of $875.73 million during the quarter, compared to analyst estimates of $832.66 million. During the same quarter in the previous year, the business earned $0.86 EPS. Endo International PLC’s revenue for the quarter was down 4.9% compared to the same quarter last year. On average, analysts expect Endo International PLC to post $3.49 EPS for the current fiscal year and $3 EPS for the next fiscal year.
In other Endo International PLC news, COO Terrance J. Coughlin acquired 20,000 shares of the company’s stock in a transaction dated Thursday, August 10th. The stock was acquired at an average cost of $7.70 per share, with a total value of $154,000.00. Following the purchase, the chief operating officer now directly owns 181,369 shares in the company, valued at approximately $1,396,541.30. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Paul Campanelli acquired 6,500 shares of the company’s stock in a transaction dated Monday, August 14th. The shares were acquired at an average cost of $7.71 per share, with a total value of $50,115.00. Following the completion of the purchase, the chief executive officer now owns 213,620 shares in the company, valued at $1,647,010.20. The disclosure for this purchase can be found here. Over the last three months, insiders have bought 36,000 shares of company stock valued at $279,460. Corporate insiders own 0.50% of the company’s stock.
A number of equities research analysts recently commented on ENDP shares. Oppenheimer Holdings, Inc. restated a “hold” rating on shares of Endo International PLC in a research report on Sunday, July 23rd. ValuEngine downgraded shares of Endo International PLC from a “buy” rating to a “hold” rating in a research report on Friday, September 1st. Deutsche Bank AG reduced their price objective on shares of Endo International PLC from $18.00 to $15.00 and set a “buy” rating for the company in a research report on Friday, July 7th. Zacks Investment Research upgraded shares of Endo International PLC from a “hold” rating to a “buy” rating and set a $9.75 price objective for the company in a research report on Wednesday, October 11th. Finally, BidaskClub upgraded shares of Endo International PLC from a “sell” rating to a “hold” rating in a research report on Wednesday, July 19th. Four analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and five have issued a buy rating to the company’s stock. Endo International PLC has a consensus rating of “Hold” and a consensus price target of $12.64.
TRADEMARK VIOLATION WARNING: “Endo International PLC (ENDP) Scheduled to Post Quarterly Earnings on Thursday” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another publication, it was stolen and republished in violation of United States & international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/11/02/endo-international-plc-endp-scheduled-to-post-quarterly-earnings-on-thursday.html.
Endo International PLC Company Profile
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with MarketBeat.com's FREE daily email newsletter.